E2212 – A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Physician and Research Staff Educational Materials:

These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.

  • Pocket Reference Card: trial schema, study objectives, and eligibility requirements on a pocket-sized card for easy reference when consulting with patients in the office or on rounds.
  • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study.

steven-libuttiE2212 Webinar: Steven K. Libutti, MD (Albert Einstein College of Medicine and the Montefiore Medical Center), study chair, hosted a webinar in December 2014 for investigators and other research personnel interested in enrolling patients to this trial. Dr. Libutti provided an overview of the study based on protocol version 04/21/2014 (view Dr. Libutti’s bio). The webinar slides are posted on ECOG.org and CTSU.org (passwords required). Other inquiries about this webinar may be directed to the ECOG-ACRIN Clinical Education and Awareness Team via email.

 
Information and Assistance from the National Cancer Institute:

  • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

Additional Information on ClinicalTrials.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT02031536.